Navigation Links
James F. Szigethy Named Curemark's Director of New Product Development
Date:9/7/2010

RYE, N.Y., Sept. 7 /PRNewswire/ -- Curemark (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that James F. Szigethy, formerly a consultant for Curemark, has assumed the position of Director of New Product Development.  In his new position, Szigethy will have direct oversight of improving existing products and directing the development of new products.  As Curemark continues to anticipate expansion of its clinical trials program, Szigethy will oversee and coordinate all activities across a variety of Curemark product programs, the company said.

Dr. Joan Fallon, Curemark's Founder and CEO said, "We are very excited  to have James assume this new position.  Curemark has a strong focus on innovation coupled with excellence and James' credentials as an experienced pharmacist and consultant are a tremendous asset to us."

"I am excited to have the opportunity to implement Curemark's strategic vision and this is a truly exciting company to work for," remarked Szigethy.  "Curemark is focused on children with conditions for whom either no treatment or inadequate treatment is available and I am proud to be at the forefront of the development of new products to further our studies and Curemark's mission."

Szigethy's new responsibilities will include formulation development, overseeing Curemark's product production and expansion of its product portfolio. He has been with the company since 2007.

Szigethy graduated from St. John's University in 1994 with a B.A. in Psychology. He attained his B.S. in Pharmacy in 2001 and became a supervising pharmacist for Wal-Mart, where his department was recognized as Wal-Mart's Northeast Region Pharmacy of the Year in 2006.

Curemark currently is conducting Phase III clinical trials for CM-AT, an autism treatment that will be one of the first to address the underlying physiology of autism.  CM-AT is based on Dr. Fallon's breakthrough research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function.  The FDA has designated CM-AT as a Fast Track drug.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thoratec Presentation at Raymond James Conference to Be Webcast
2. Hill-Rom Announces Appointment of James R. Giertz to Board of Directors
3. AMD LASERS Names Dr. James Jesse as Medical Director
4. Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
5. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
6. Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100
7. Cape Medical Supply Named to Prestigious Inc. 5000 List of Americas Fastest Growing Private Companies for Fourth Year in a Row
8. SAM Medical Products Named to Inc. 5000 List of the Fastest-Growing Private Companies in America
9. MedNet Solutions Named to the Inc. 5000 List of Fastest Growing Companies for the Fourth Consecutive Year
10. BlueDot Medical, Inc. Named to 2010 Inc. 500/5000
11. KPaul Named to the Inc. 500 Fastest Growing Companies List for 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017   Divoti USA ... Jewelry up to the standard of the latest FDA requirements, which ... 2017). Anyone in need of Medical ID jewelry such ... Alert Jewelry are engraved in terms of the new ... Divoti offers ...
(Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief ... advancements to physician colleagues, skilled nursing facility medical directors and other clinicians at ... of Wound Care." , "At many of these conferences we get to educate ...
Breaking Medicine News(10 mins):